BC Innovations | Aug 8, 2019
Distillery Techniques

Nanoparticle-based system for nucleic acid therapy delivery and monitoring of disease progression in thoracic aortic dissection

TECHNIQUES CATEGORY: Drug delivery; imaging TECHNOLOGY: Nanoparticles; MRI A nanoparticle-based system could deliver a nucleic acid therapy to thoracic aortic dissections to treat and non-invasively monitor earlier progression of the disease, which current methods cannot...
BC Innovations | Jul 17, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer; lung cancer Patient sample and mouse studies suggest miR-130a and miR-145 or their mimics could help treat breast and lung cancers. In tumor samples from patients with breast or lung cancers, low...
BC Innovations | Jul 9, 2015
Distillery Therapeutics

Therapeutics: microRNA-145 (miR-145)

Cardiovascular disease INDICATION: Hypertension; Pulmonary Rat studies suggest cationic lipopolyamine-based nanoparticles loaded with small RNA-based therapeutics could help treat pulmonary arterial hypertension (PAH) and other lung diseases. In a rat model of PAH, nanoparticles loaded...
BC Innovations | Jun 25, 2015
Translation in Brief

Celsion's silent approach

Drug delivery Celsion Corp. (NASDAQ: CLSN) has discovered that its TheraSilence delivery platform delivers RNA-based therapeutics efficiently to the lung - a feat beyond most RNA delivery systems, which on the whole reach only the liver....
BC Week In Review | Jul 1, 2013
Clinical News

Egen preclinical data

In a rat model of PAH, IV administration of a microRNA-145 inhibitor using Egen's Staramine-mPEG delivery system significantly reversed pulmonary hypertension and improved cardiovascular function. Data were presented at the American Thoracic Society meeting in...
BC Innovations | Apr 18, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Head and neck cancer ADAM17; microRNA-145 (miR-145); SRY (sex determining region Y)-box 9 (SOX9); IL-6 Mouse and cell culture studies suggest increasing miR-145 expression could...
BC Week In Review | Mar 11, 2013
Company News

miRagen, University of Glasgow deal

The university granted miRagen exclusive rights to IP covering microRNA-145 . The IP was discovered under a deal between the university, biotech and University of Cambridge (Cambridge, U.K.) to develop the target to treat pulmonary arterial...
BC Innovations | Jan 13, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer MicroRNA-143 (miR-143); miR-145 Studies in mice and in zebrafish suggest that increasing miR-143 and miR-145 levels could help treat...
BC Week In Review | Oct 26, 2009
Clinical News

Geniom Real Time Analyzer: Postmarketing study data

GRTA identified 165 miRNAs that were significantly up- or down-regulated in patients with relapsing-remitting MS (RRMS) vs. healthy controls. The most significantly deregulated biomarker, has-miR-145, discriminated between RRMS patients and healthy controls with 89.7% accuracy,...
BC Innovations | May 14, 2009
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms MicroRNA-145 to control human embryonic stem cell (hESC) pluripotency and differentiation In vitro studies suggest that targeting miRNA-145 could help control...
Items per page:
1 - 10 of 10